# A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast

Source: https://onco.cc/trials/nct07784374/  
OnCo record `nct07784374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GFH375 in pancreatic cancer, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.

## Summary

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation is a phase 2, randomised interventional study registered as NCT07784374 by Genfleet Therapeutics (Shanghai) Inc., with a registry enrolment figure of 120 participants, started 2026-08-31 and due to reach its primary completion in 2028-08-31. Interventions recorded: GFH375; GFH276; GFS202A. Conditions listed: Pancreatic Cancer. Primary outcome: PFS; Weight. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed pancreatic adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-19
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07784374
- Phase: 2
- Setting: A Phase II, Multicenter, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of GFH375 in Combination With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 120

## Notes

- Registry status on 19 October 2026: Recruiting (registry record last updated 2 October 2026; primary completion expected 31 August 2028).

## Sources

- ClinicalTrials.gov NCT07784374: https://clinicaltrials.gov/study/NCT07784374

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [GFH375](https://onco.cc/drugs/gfh375/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07784374.json